Latest Hospitality News

Hydrix has secured a three-year contract with Singapore’s National Heart Centre to deploy the Implicity remote cardiac monitoring platform. The agreement is expected to generate about A$0.625 million, although the final value depends on patient volumes and implementation.

Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.

EMVision has completed the first stage of a Melbourne Mobile Stroke Unit study, operating its portable brain scanner in homes, ambulances and a workplace. The small, non-diagnostic feasibility study produced strong usability results while pointing to a larger clinical validation step planned for next-generation units.

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

HealthCo Healthcare & Wellness REIT says lenders have backed the proposed transfer of operations at 10 Healthscope hospitals owned by HCW and its unlisted fund. The transaction remains subject to customary approvals, but Healthscope has paid all rent due through September 2026.

Kingfish’s adjusted NAV rose 1.2% in August, broadly matching the NZX benchmark as Vista, Fisher & Paykel Healthcare and Delegat delivered the strongest portfolio gains. The fund still trades at a 7.5% discount to NAV, while its one-year shareholder return remains negative.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

Arovella Therapeutics has released the first clinical batch of its off-the-shelf cell therapy ALA-101 and activated its inaugural trial site at The Alfred, setting the stage for patient dosing later this month.

FlexiRoam has inked a two-year deal with Dragonpass, embedding its eSIM data rewards into a major hotel loyalty program and marking its first foray into travel loyalty and hospitality.

EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.

IMEXHS Limited reported a 12% rise in annual recurring revenue to $36.8 million in 1H FY26, powered by its AI-enabled radiology platform now live in a public hospital network. Underlying EBITDA surged 311% to $1.27 million despite ongoing sector liquidity challenges in Colombia.